Kesler Norman & Wride LLC Has $8.41 Million Position in Cencora, Inc. (NYSE:COR)

Kesler Norman & Wride LLC reduced its holdings in shares of Cencora, Inc. (NYSE:COR) by 5.6% in the third quarter, according to its most recent filing with the SEC. The fund owned 37,365 shares of the company’s stock after selling 2,228 shares during the period. Cencora comprises 1.7% of Kesler Norman & Wride LLC’s portfolio, making the stock its 8th biggest position. Kesler Norman & Wride LLC’s holdings in Cencora were worth $8,411,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Rise Advisors LLC bought a new stake in Cencora during the 1st quarter valued at $25,000. New Millennium Group LLC purchased a new position in shares of Cencora in the 2nd quarter valued at $26,000. TCTC Holdings LLC purchased a new position in shares of Cencora in the 1st quarter valued at $29,000. TFO Wealth Partners LLC purchased a new position in shares of Cencora in the 1st quarter valued at $30,000. Finally, MFA Wealth Advisors LLC purchased a new position in shares of Cencora in the 2nd quarter valued at $30,000. 97.52% of the stock is owned by institutional investors.

Cencora Price Performance

NYSE:COR opened at $219.50 on Tuesday. Cencora, Inc. has a 12 month low of $182.62 and a 12 month high of $247.66. The stock has a 50 day moving average of $234.45 and a two-hundred day moving average of $231.91. The company has a current ratio of 0.89, a quick ratio of 0.55 and a debt-to-equity ratio of 3.93. The firm has a market cap of $43.78 billion, a P/E ratio of 24.02, a price-to-earnings-growth ratio of 1.58 and a beta of 0.44.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.18 by $0.16. The business had revenue of $74.20 billion during the quarter, compared to analyst estimates of $73.32 billion. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The business’s revenue was up 10.8% compared to the same quarter last year. During the same period in the prior year, the business earned $2.92 earnings per share. On average, analysts expect that Cencora, Inc. will post 13.63 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 9th were given a $0.51 dividend. The ex-dividend date was Friday, August 9th. This represents a $2.04 annualized dividend and a yield of 0.93%. Cencora’s payout ratio is 22.32%.

Insider Buying and Selling

In related news, CEO Steven H. Collis sold 10,755 shares of the stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total value of $2,388,900.60. Following the completion of the transaction, the chief executive officer now directly owns 285,088 shares in the company, valued at approximately $63,323,746.56. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Cencora news, CEO Steven H. Collis sold 10,755 shares of the company’s stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total transaction of $2,388,900.60. Following the transaction, the chief executive officer now directly owns 285,088 shares in the company, valued at $63,323,746.56. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Silvana Battaglia sold 1,473 shares of the company’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total value of $357,482.37. Following the transaction, the executive vice president now owns 10,948 shares in the company, valued at $2,656,970.12. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 4,450,399 shares of company stock worth $1,070,392,799. Company insiders own 15.80% of the company’s stock.

Wall Street Analyst Weigh In

COR has been the topic of several research analyst reports. StockNews.com downgraded Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. Robert W. Baird dropped their price target on Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a research note on Friday, September 6th. Wells Fargo & Company boosted their price target on Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a research note on Thursday, August 1st. JPMorgan Chase & Co. boosted their price target on Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research note on Wednesday, August 21st. Finally, Bank of America reissued a “neutral” rating and issued a $245.00 price objective (down previously from $275.00) on shares of Cencora in a report on Wednesday, September 18th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $256.67.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.